KEYNOTE-181: Phase 3, open-label study of second-line pembrolizumab vs single-agent chemotherapy in patients with advanced/metastatic esophageal adenocarcinoma.

被引：6
|
作者：
Doi, Toshihiko
Bennouna, Jaafar
Shen, Lin
Enzinger, Peter C.
Wang, Ruixue
Csiki, Ildiko
Koshiji, Minori
Shah, Manish A.
机构：
[1] Natl Canc Ctr Hosp East, Chiba, Japan
[2] Inst Cancerol Ouest, Nantes, France
[3] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] MSD China, Beijing, Peoples R China
[6] Merck & Co Inc, Kenilworth, NJ USA
[7] Merck & Co Inc, Rahway, NJ 07065 USA
[8] Weill Cornell Med Coll, New York, NY USA
[9] New York Presbyterian Hosp, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS4140
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4140
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase III, randomized, open-label study to compare the efficacy of tislelizumab versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC)
    Shen, L.
    Ajani, J. A.
    Kim, S-B.
    Van Cutsem, E.
    Guo, B.
    Song, J.
    Paton, V.
    Kato, K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [22] A Single-arm, Multicenter, Open-label Phase 2 Study of Lapatinib as the Second-line Treatment of Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma
    Wuelfing, Christian
    Machiels, Jean-Pascal H.
    Richel, Dirk J.
    Grimm, Marc-Oliver
    Treiber, Uwe
    De Groot, Marco R.
    Beuzeboc, Philippe
    Parikh, Roma
    Petavy, Frank
    El-Hariry, Iman A.
    CANCER, 2009, 115 (13) : 2881 - 2890
  • [23] Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study
    Finn, R.
    Chan, S. L.
    Zhu, A. X.
    Knox, J.
    Cheng, A-L.
    Siegel, A.
    Bautista, O.
    Watson, P. A.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [24] A phase II study of single-agent nab-paclitaxel as second-line therapy in patients with metastatic urothelial carcinoma
    Sridhar, S. S.
    Canil, C. M.
    Mukherjee, S. D.
    Winquist, E.
    Elser, C.
    Eisen, A.
    Chung, A.
    Ko, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] A phase 3, randomized, open-label study to compare the efficacy of tislelizumab (BGB-A317) versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).
    Shen, Lin
    Ajani, Jaffer A.
    Kim, Sung-Bae
    Van Cutsem, Eric
    Guo, Baohong
    Song, James
    Paton, Virginia
    Kato, Ken
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] A single-arm, open-label, prospective, multicenter study of apatinib combined with chemotherapy as second-line therapy in patients with advanced gastric cancer
    Feng, J.
    Shen, B.
    Xu, J.
    Wang, Q.
    Ling, G.
    Mao, Y.
    Cai, M.
    Yang, Y.
    Mei, J.
    Han, Z.
    Wu, Y.
    Shi, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S913 - S913
  • [27] An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer.
    Fields, ALA
    Rinaldi, DA
    Henderson, CA
    Germond, CJ
    Chu, L
    Brill, KJ
    Leopold, LH
    Berger, MS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 266S - 266S
  • [28] Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
    Yap, Timothy A.
    Nakagawa, Kazuhiko
    Fujimoto, Nobukazu
    Kuribayashi, Kozo
    Guren, Tormod Kyrre
    Calabro, Luana
    Shapira-Frommer, Ronnie
    Gao, Bo
    Kao, Steven
    Matos, Ignacio
    Planchard, David
    Chatterjee, Arkendu
    Jin, Fan
    Norwood, Kevin
    Kindler, Hedy L.
    LANCET RESPIRATORY MEDICINE, 2021, 9 (06): : 613 - 621
  • [29] Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study
    Wang Feng
    Wang Junsheng
    Wu Tao
    Hong Yonggui
    Meng Xiangrui
    Ren Zhonghai
    Guo Yanzhen
    Yang Xiuli
    Shi Pei
    Yang Jiamei
    Fan Qingxia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [30] A single arm, multicenter, open-label phase II study of orally administered GW572016 as single-agent, second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract.: Interim analysis.
    Machiels, JP
    Wülfing, C
    Richel, DJ
    Beuzeboc, P
    Del Muro, XG
    Grimm, MO
    Farrell, J
    Colman, JR
    El-Harity, IA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 410S - 410S
12345